PLAYDASH Media
August 5, 2026
Press Release — Source: PR Newswire Asia. Content supplied by the issuing organization.
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme ™ -based hyaluronidase ALT-B4
Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, regulatory and sales milestone payments
Additional royalties to be paid based on net sales following commercialization
DAEJEON, South Korea , Aug. 5, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it has entered into an exclusive license agreement with a global pharmaceutical company for the development and commercialization of a subcutaneous (SC) biologic product utilizing ALT-B4
